Shimobi C. Onuoha

This paper introduces AbNatiV2 and p-AbNatiV2, deep learning models for assessing nativeness and pairing likelihood in antibodies and nanobodies, showing improved performance on held-out tests.

This paper develops an in vivo CAR T cell platform using lipid nanoparticles and T-trex strategy to enhance safety, efficacy, and tumor control.

This paper develops a novel CAR-T cell therapy for glioblastoma that overcomes immunosuppression and improves persistence through a multi-armoured design.

NanoMelt, a ridge-stacked ensemble of regressors on four diverse sequence embeddings, predicts nanobody melting temperature from 640 curated sequences, reaching Spearman 0.832 under nested cross-validation.

The paper develops a small-molecule control system using minocycline to disrupt protein-protein interactions for reversible and dose-dependent control of therapeutic applications.